Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.43 |
| ▸ | SKP1 | P63208 | 2/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850285 | 0.84 | DPP4 (0.47) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL27719009 | 0.80 | MAPT (0.39) | MAPTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4808063 | 0.80 | ALDH1A1 (0.57) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL2824232 | 0.78 | CKS1B (0.48) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL2830810 | 0.77 | ATM (0.47) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL19056939 | 0.76 | CKS1B (0.44) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL12193543 | 0.75 | HRH3 (0.55) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL4573137 | 0.75 | CTSB (0.46) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL21303031 | 0.75 | HRH3 (0.53) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL4850288 | 0.74 | PPARG (0.46) | CKS1BSKP1SKP2MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-1838308-A1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | CKS1B 3454/4885SKP1 1330/4885SKP2 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.